注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Aura Biosciences Inc是一家臨床階段的生物技術公司,專注於開發病毒樣藥物偶聯物 (VDC),這是一種用於治療多種腫瘤適應症的新型療法。該公司的主要VDC候選藥物AU-011(belzupacap sarotalocan)由與抗癌劑結合的病毒樣顆粒組成。 AU-011由人乳頭瘤病毒 (HPV) 衍生的類病毒顆粒(VLP)與數百個紅外激光激活分子結合而成。 AU-011選擇性地靶向和破壞癌細胞並激活免疫系統,有可能產生持久的抗腫瘤免疫。 AU-011正在開髮用於眼癌,正在進行的II期劑量遞增臨床試驗評估脈絡膜黑色素瘤的一線治療。該公司尋求在其眼部腫瘤專營權中開發AU-011,包括治療脈絡膜轉移患者。此外,該公司正在開髮用於治療非肌肉浸潤性膀胱癌的AU-011。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Rajesh Bhikhu Parekh | 63 | 2015 | Independent Director |
Karan S. Takhar | 32 | 2021 | Independent Director |
David Michael Johnson | 57 | 2021 | Independent Chairman of the Board |
John T. Schiller | - | 2021 | Member of Scientific Advisory Board |
Sapna Srivastava | 52 | 2021 | Independent Director |
Arun D. Singh | - | - | Scientific & Clinical Advisor |
Giovanni Mariggi | 37 | 2019 | Independent Director |
Elisabet de los Pinos | 49 | 2007 | Founder, CEO, President & Director |
Jay S. Duker | 64 | - | Scientific & Clinical Advisor |
Evangelos S. Gragoudas | - | - | Scientific & Clinical Advisor |
Carol L. Shields | - | - | Scientific & Clinical Advisor |
Brian Marr | - | - | Scientific & Clinical Advisor |
Richard Carvajal | - | - | Scientific & Clinical Advisor |
Antony Mattessich | 56 | 2021 | Independent Director |
Isaac Yi Kim | - | 2021 | Member of Scientific Advisory Board |
Seth P. Lerner | - | 2021 | Member of Scientific Advisory Board |
Gary Steinberg | - | 2024 | Member of Scientific Advisory Board |
Andrea Apolo | - | 2021 | Member of Scientific Advisory Board |
Max Kates | - | 2023 | Member of Scientific Advisory Board |
Neal D. Shore | - | 2023 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核